EP1005492B1 - Purification du facteur de von willebrand par chromatographie sur echangeur de cations - Google Patents

Purification du facteur de von willebrand par chromatographie sur echangeur de cations Download PDF

Info

Publication number
EP1005492B1
EP1005492B1 EP98901870A EP98901870A EP1005492B1 EP 1005492 B1 EP1005492 B1 EP 1005492B1 EP 98901870 A EP98901870 A EP 98901870A EP 98901870 A EP98901870 A EP 98901870A EP 1005492 B1 EP1005492 B1 EP 1005492B1
Authority
EP
European Patent Office
Prior art keywords
vwf
preparation
activity
fraction
nacl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98901870A
Other languages
German (de)
English (en)
Other versions
EP1005492A1 (fr
Inventor
Bernhard Fischer
Öyvind L. SCHÖNBERGER
Artur Mitterer
Christian Fiedler
Friedrich Dorner
Johann Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Publication of EP1005492A1 publication Critical patent/EP1005492A1/fr
Application granted granted Critical
Publication of EP1005492B1 publication Critical patent/EP1005492B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to a method for obtaining a purified von Willebrand factor (vWF) by means of cation exchange chromatography.
  • vWF von Willebrand factor
  • the vWF circulates in a concentration of 5 - 10 mg / l partly in the form of a non-covalent complex with factor VIII.
  • the vWF is a glycoprotein, which is formed in various cells of the human body and later released into the circulation.
  • a vWF dimer (primary vWF dimer) having a molecular weight of about 450000 Da is synthesized in the cells by formation of several sulfur bridges. From the vWF dimers, in turn, by linking via sulfur bridges, further polymers of the vWF with ever higher molecular weights, up to about 20,000,000 Da, are produced.
  • vWF ristocetin cofactor activity
  • vWF ristocetin cofactor activity
  • Ag ratio between activity and vWF antigen concentration
  • the vWF fulfills important functions in the context of hemostasis. It circulates in the plasma partly as a complex with factor VIII, which supports blood coagulation as a cofactor. Factor VIII is stabilized by complex formation with vWF and protected from proteolytic degradation. Another task of the vWF is its involvement in platelet aggregation, which makes an important contribution to primary hemostasis.
  • the vWF binds to the glycoproteins Ib and IIb / IIIa of the surface receptors of the Platelets and thus cross-links the platelets to a platelet aggregate.
  • vWF is a component of the extracellular matrix that does not have direct contact with the blood in intact vessels because it is shielded from the bloodstream by a monolayer of endothelial cells.
  • endothelial cell layer is shielded from the bloodstream by a monolayer of endothelial cells.
  • the vWF is able to fix the forming platelet aggregate in the damaged vascular area on the exposed subendothelium. This results in a first, labile wound closure, which is solidified by the subsequent blood clotting.
  • Von Willebrand syndrome is characterized by a deficiency of a functional von Willebrand factor or by an abnormal spectrum in the multimer composition of von Willebrand factor.
  • Patients with von Willebrand syndrome may experience factor VIII deficiency due to the lack of stabilization of factor VIII, despite the normally normal factor VIII synthesis rate, due to the greatly reduced plasma half-life of this coagulation factor. Therefore, patients with von Willebrand syndrome may experience symptoms similar to hemophilia A patients (phenotypic hemophilia). Lack of functionally active vWF may also result in dysfunctional platelet aggregation and adhesion in patients with von Willebrand syndrome, which may lead to defects in primary hemostasis. Due to disturbances of these vWF-mediated processes, patients with von Willebrand's syndrome show prolonged bleeding times.
  • vWF preparations For the treatment of von Willebrand syndrome therefore vWF preparations must be administered, which compensate for the lack of functionally active vWF.
  • preparations can be used which are also used for the treatment of hemophilia A, such as cryoprecipitate or factor VIII concentrates prepared therefrom, which contain complexes of factor VIII and vWF.
  • hemophilia A such as cryoprecipitate or factor VIII concentrates prepared therefrom, which contain complexes of factor VIII and vWF.
  • C concentrates are used, which do not contain the vWF or only in traces.
  • vWF preparation would be as free as possible of contaminating factor VIII is particularly desirable for the treatment of von Willebrand syndrome. Therefore, there is a need for pure and virus safe von Willebrand factor preparations with high specific activity.
  • EP 0 503 991 describes the purification of vWF from human cryoprecipitate by three successive chromatographic steps: 1. anion exchange chromatography on TSK-DEAE-Fractogel and elution of vWF by 0.15 M NaCl; 2. Repeated anion exchange chromatography on TSK-DEAE-Fractogel and elution of the vWF by 0.17 M NaCl and 3. affinity chromatography on gelatin-Sepharose to remove the contaminating fibrinogen. In this case, amino acid and calcium ion-containing buffers were used.
  • WO 89/12065 describes the separation of plasmatic vWF from factor VIII and other proteins by binding of the proteins to an anion exchanger and stepwise elution by increasing the salt concentration.
  • the vWF-containing fraction was chromatographed a second time over an anion exchanger and recovered as a concentrate.
  • EP 0 469 985 discloses the purification of plasmatic vWF from cryoprecipitate, wherein in a first step factor VIII is selectively bound to an anion exchanger at a salt concentration of 250 mM while vWF remains in the supernatant. After lowering the salt concentration of the vWF-containing supernatant to a salt concentration between 100 mM and 150 mM, vWF is bound to a second anion exchanger and eluted at pH 6.6 with 300-350 mM NaCl. This will be vWF with an activity of at least 50 U / mg containing a fraction of factor VIII of ⁇ 2%.
  • DE 39 04 354 describes the recovery of plasmatic vWF from cryoprecipitate and the separation of vWF from factor VIII by selective adsorption of factor VIII to an anion exchanger, while vWF remains in solution. In this case, a solution containing 160 U / ml vWF is obtained.
  • EP 0 383 234 describes the preparation of a vWF concentrate by means of anion exchange chromatography in which a factor VIII / vWF complex contained in a solution is dissociated by addition of a calcium- and amino acid-containing buffer and a vWF concentrate is obtained.
  • WO 96/10584 describes a method for obtaining highly purified recombinant vWF by means of combined anion exchange / heparin affinity chromatography and EP 0 705 846 describes the separation of high and low molecular weight fractions of recombinant vWF by means of heparin affinity chromatography.
  • WO93 / 15199 describes the use of albumin for the production of albumin fusion proteins as carriers for various proteins.
  • As an optional component of such a fusion protein small fragments of the vWF are mentioned for preventing adhesion to vWF and platelets.
  • the object of the present invention is to provide a method for the production of purified vWF with improved specific activity which is suitable for large-scale industrial scale use.
  • the procedure should be used for both recombinant and plasmatic vWF purification be usable.
  • the object is achieved by providing a method for obtaining vWF in which vWF is bound to a cation exchanger at a (low) salt concentration of ⁇ 250 mM and by stepwise, fractionated elution at a salt concentration of> 300 mM vWF, consisting in particular of high molecular weight vWF multimers with high specific activity, is obtained.
  • vWF with improved activity and stability is in particular characterized in that by fractional increase in the salt concentration first fractions containing low molecular weight vWF multimers, inactive degradation products and unspecific accompanying proteins are separated at an average salt concentration and fractions containing high molecular weight vWF multimers with high specific activity, be obtained at a higher salt concentration.
  • the process according to the invention gives purified fractions starting from an impure biological material which are substantially free from contaminating nucleic acids.
  • the method also removes nucleic acids from protein preparations. This effect can not be demonstrated by conventional methods using anion exchangers, since nucleic acids due to bind their negative charge to the anion exchanger, replace by increasing the salt concentration again from the anion exchanger and get into the eluate.
  • any known cation exchanger can be used to carry out the process, with cation exchangers having a support which is sulfopropyl- or carboxymethyl-group-conjugated being preferred.
  • cation exchangers having a support which is sulfopropyl- or carboxymethyl-group-conjugated being preferred.
  • SP-Sepharose ® Fast Flow and CM-Sepharose ® Fast Flow Pulharmacia
  • Fractogel ® EMD-SO3 Fractogel ® EMD COOH (Merck)
  • Poros ® 10 SP and Poros ® 10 S Perseptive Biosystems
  • Toyopearl TM SP 550 C and Toyopearl TM CM-650 (M) TosoHaas).
  • the adsorption of the vWF to the cation exchanger is preferably carried out at a salt concentration in the buffer of 250 mM.
  • Preferred Adsoprtionspuffer therefore have a salt concentration of 50 to 250 mM, in particular in the range of 150 mM - 250 mM (eg 150 mM).
  • By gradually increasing the salt concentration in the buffer selectively vWF consisting essentially of high molecular weight vWF multimers can be eluted at a salt concentration> 300 mM.
  • Low molecular weight vWF multimers and proteolytic vWF degradation products contained in the vWF-containing solution and having low vWF activity specific activity, in particular ristocetin cofactor activity, collagen binding activity, and specific platelet agglutination activity are interposed at a salt concentration > 250 mM and ⁇ 300 mM, preferably eluted from the cation exchanger at 300 mM and separated.
  • the adsorption and desorption of the vWF can be carried out in a buffer containing as salt a mono- or divalent metal ion, NaCl being used as the salt.
  • a buffer solution consisting of buffer substances, in particular glycine, phosphate buffer or citrate buffer, and salt is preferably used as the buffer system for elution of the proteins bound to the cation exchanger.
  • the buffer used preferably contains no Ca ions.
  • the elution buffer may have a pH in the pH range between 5.0 to 8.5, preferably between 6.0 and 8.0.
  • the process according to the invention can be carried out as a batch process or as a column chromatography.
  • the optimal parameters such as salt concentration, pH and temperature for carrying out the process according to the invention are each dependent on the cation exchanger material used.
  • a vWF is obtained and enriched by the method according to the invention, which consists in particular of high molecular weight vWF multimers.
  • Low molecular weight vWF multimers and vWF fragments with low specific platelet agglutination activity are selectively separated to contain fractions
  • high molecular weight vWF multimers with high activity and specificity can be obtained.
  • the recovered vWF fraction (s) is (are) substantially free of low molecular weight vWF multimers, low specific activity vWF fragments, Factor VIII complex, Factor VIII: C, non-specific companion proteins, and contaminating nucleic acids.
  • any vWF-containing solution can be used.
  • Starting materials are in particular biological materials such as plasma, a plasma fraction, cryoprecipitate, or a supernatant or an extract of a recombinant cell culture.
  • vWF-containing solutions may also be enriched protein solutions that have been prepurified by a previous purification step, such as by gel filtration, anion exchange chromatography, affinity chromatography, or a combination thereof.
  • a previous purification step such as by gel filtration, anion exchange chromatography, affinity chromatography, or a combination thereof.
  • the starting solution used is a vWF-containing fraction enriched in an anion exchanger.
  • vWF By means of anion exchange chromatography, depending on the manner of carrying out the anion exchange chromatography, vWF either as an unbound material, the anion exchanger can pass freely or adsorb to it.
  • vWF is recovered and enriched from a plasma fraction by binding both vWF and Factor VIII / vWF complex to an anion exchanger at low ionic strength and salt concentration in a weakly acidic medium.
  • vWF is then selectively eluted from the anion exchanger at a mean salt concentration of 150mM to 250mM, while Factor VIII complex and free, not complexed factor VIII desorb at a high salt concentration of> 300 mM.
  • An enriched vWF fraction can also be obtained by treating an vWF-containing solution at an average salt concentration between 100 mM and 200 mM with an anion exchanger, whereby Factor VIII complex binds to the anion exchanger while vWF remains in solution. Bound factor VIII complex can then be recovered from the anion exchanger by increasing the salt concentration.
  • the vWF present in an enriched solution with a salt concentration of 250 mM is obtained directly from the flow or eluate or as a supernatant (in the batch process) and optionally bound to the cation exchanger without changing the ionic strength or salt concentration.
  • the salt concentration may be lowered by dilution.
  • This embodiment has the particular advantage that a simple combination of anion / KationenSerchromatographie is possible without complex Umpuff für chromatographie, dialysis or similar. the enriched proteins.
  • an enriched vWF-containing fraction can be obtained by a first chromatographic step and purification and separation of high molecular weight and low molecular weight vWF fractions can be achieved by subsequent cation exchange chromatography.
  • affinity / cation exchange chromatography anion exchange / affinity / cation exchange chromatography are also possible to achieve further enrichment and selective recovery of vWF with high specific activity.
  • vWF with high specific activity is enriched at least 80-fold from an impure vWF-containing material.
  • the recovered vWF-containing fraction is treated for the inactivation or depletion of viruses.
  • all known from the prior art methods such as chemical / physical methods, inactivation by combining a photoactive substance and light or depletion can be used by filtration.
  • Inactivating viruses is particularly suitable for heat treatment in solution or in the solid state, which can reliably inactivate both lipid-enveloped and non-lipid-enveloped viruses.
  • Virus depletion is preferably carried out by filtration through nanofilters.
  • the present invention provides a preparation containing purified high specific activity vWF, consisting in particular of high molecular weight vWF multimers, obtainable from a vWF-containing solution by cation exchange chromatography according to the present invention.
  • High specific activity vWF is enriched from a starting material containing, inter alia, low purity, low specific activity, vWF, and selectively isolates accessory proteins, particularly Factor VIII or Factor VIII complex containing low molecular weight vWF multimers.
  • a preparation containing purified vWF which consists in particular of high molecular weight vWF multimers and essentially contains no low molecular weight vWF multimers and vWF degradation products, is obtained.
  • the preparation according to the invention has a specific platelet agglutination activity of vWF of at least 65 U / mg protein and a specific collagen binding activity of at least 65 U / mg protein.
  • the preparation is characterized by being substantially free of factor VIII and having a factor VIII content of ⁇ 0.1% with respect to the ratio of vWF to factor VIII activity.
  • nucleic acid can also be quantified according to a method as described, for example, in EP 0 714 987 and EP 0 714 988.
  • a virus removal or inactivation method is optionally carried out to remove infectious particles, virus inactivation and / or virus depletion principally before or after each purification step starting from the starting material to the prepared pharmaceutical preparation can be carried out.
  • the preparation of the invention is virus-safe in any case.
  • the preparation according to the invention is in a storage-stable form.
  • the preparation containing purified high specific activity vWF may be provided as a ready-to-use solution, lyophilizate or frozen. Due to its purity, the preparation is particularly stable.
  • the preparation of the invention is stable at -20 ° C for at least 6 months, at 4 ° C in solution for at least 4 weeks and as a lyophilisate for at least 1 year. It was found that within the respective period the vWF activity is reduced by a maximum of 10% and also the multimer pattern of the vWF multimers shows no significant change.
  • the formulation of the preparation according to the invention can be carried out in a conventional manner.
  • the purified vWF contained in the preparation according to the invention is mixed with a buffer containing salts such as NaCl, trisodium citrate dihydrate and / or CaCl 2 , and amino acids such as glycine and lysine at a pH in the range of 6 to 8 and as a pharmaceutical Preparation formulated.
  • the preparation can be used to prepare a medicament for the treatment of patients with phenotypic hemophilia and vWD.
  • Example 1 describes the purification of rvWF from culture supernatants of recombinant cells by means of cation exchange chromatography;
  • Example 2 describes the purification of plasmatic vWF by cation exchange chromatography and upstream anion exchange chromatography;
  • Example 3 describes the purification of recombinant vWF by combined anion exchange / immunoaffinity and cation exchange chromatography.
  • vWF was in recombinant CHO cells in a standard culture medium produced. After fermentation of the transformed cells, the culture medium was removed and cells and cell debris were removed by centrifugation. Subsequently, the solution for removing low-molecular components, such as membrane fragments, was clarified by filters with pore size of 0.4 microns.
  • a chromatography column (50 ml) was filled with a cation exchanger (Fractogel ® EMD-SO3) and diluted with buffer (30 mM glycine-NaC1 buffer) rinsed. Subsequently, the cation-exchange column was loaded with the cell-free culture supernatant, whereby those proteins which do not bind to the exchanger were obtained in the flow (fraction 1). Bound nonspecific accompanying proteins were removed by rinsing the column with buffer containing 0.3 M NaCl (fraction 2). Subsequently, bound vWF was desorbed from the exchanger with buffer containing 0.5 M NaCl and obtained in eluate (fraction 3).
  • a cation exchanger Frractogel ® EMD-SO3
  • buffer 30 mM glycine-NaC1 buffer
  • vWF antigen content vWF: Ag
  • vWF activity ristocetin cofactor activity, vWF: RistCoF
  • the protein concentration was determined by the Bradford method (Bradford, M., 1976, Anal. Biochem., 72: 248-254).
  • the content of vWF was determined by means of a commercial ELISA system (ASSERACHROM ® vWF, Boehringer Mannheim).
  • the ristocetin-CoFaktor activity was determined by means of a conventional test system (v-Willebrand-reagent ® , Behringwerke).
  • Table 1 shows the vWF multimer analysis before and after purification over the cation exchanger.
  • FIG. 1 shows the multimer analysis of vWF before and after purification by means of cation exchange chromatography.
  • lane A unpurified rvWF
  • lane B vWF multimers of fraction 1 are in the run; in lane C vWF multimers of fraction 2 (0.3 M NaCl eluate) and in lane D those of fraction 3 (0.5 M NaCl-eluate). From Figure 1 it can be seen that a vWF containing in particular high molecular weight multimers structures is obtained by cation exchange chromatography and selective elution.
  • Cryoprecipitate from human plasma was dissolved in a buffer of 7 mM Tris, 100 mM Na-acetate, 100 mM lysine at pH 6.7.
  • AL (OH) 3 was stirred in. Subsequently, the precipitate was separated by centrifugation.
  • cryoprecipitate was applied to an anion exchange column Fractogel ® EMD TMAE. Weakly bound proteins were removed by rinsing the column with a buffer containing 160 mM NaCl. By elution with 250 mM NaCl in the buffer, primarily vWF was eluted from the exchanger (fraction 1). After elution with 400 mM NaCl, FVIII complex was then eluted (fraction 2). Starting from the cryoprecipitate fraction 1 contained 68% of the total vWF activity but only 10% of the total FVIII activity. Residual vWF activity and 80% of FVIII activity are included in fraction 2.
  • vWF-containing fraction 1 was then applied to a cation exchange column Fractogel ® EMD-SO3. Weakly bound proteins were removed by rinsing the column with 100 mM NaCl. Subsequently, it was gradually eluted with 200 mM NaCl (fraction 1), 300 mM NaCl (fraction 2) and 400 mM NaCl (fraction 3). Over 70% of total vWF activity was in the 400 mM NaC1 fraction found. No FVIII: C activity was found. The results are summarized in Table 3.
  • Figure 2 shows the vWF multimer analysis during the combined anion / cation exchange chromatoraphy.
  • Lanes A to E show purification via anion exchangers and lanes F to K via cation exchangers.
  • FIG. 2 lane A shows the vWF multimer pattern of vWF in the cryoprecipitate, lane B after filtration, lane C in the passage, lane D the 250 mM NaCl eluate (fraction 1, Table 2), lane E the 400 mM NaCl Eluate (Fraction 2, Table 2), Lane F the 250 mM NaCl Eluate (Fraction 1, Table 2) before cation exchange chromatography, Lane G run, Lane H the 200 mM NaCl Eluate (Fraction 1, Table 3), lane I the 300 mM NaCl-eluate (fraction 2, Table 3) and lane K the 400 mM NaCl-eluate (fraction 3, Table 3).
  • Cryoprecipitate from human plasma was dissolved in a buffer of 7 mM Tris, 100 mM Na-acetate, 100 mM lysine, 120 mM NaCl at pH 6.7.
  • AL (OH) 3 was stirred in. Subsequently, the precipitate was separated by centrifugation.
  • cryoprecipitate was loaded onto a column of Fractogel ® EMD TMAE. Unbound proteins were obtained by rinsing the column with solution buffer (fraction 1). This fraction 1 contained 60% of the vWF activity and only 10% of the FVIII activity. Elution of the column with 400 mM NaCl (fraction 2) then gave FVIII complex.
  • the vWF-containing fraction 1 was then applied to a cation exchange column (Fractogel ® EMD S03). Weakly bound proteins were removed by rinsing the column with 100 mM NaCl. Subsequently, 200 mM NaCl (fraction 1), 300 mM NaCl (fraction 2) and 400 mM NaCl (fraction 3) were added in stages. eluted. Over 70% of the vWF activity was found in the 400 mM NaCl fraction. No factor VIII antigen and FVIII: C activity were found. The results are summarized in Table 5.
  • Figure 3 shows the vWF multimer analysis during combined anion / cation exchange chromatography.
  • Lanes a to c show purification via anion exchanger and lanes d to h via cation exchangers.
  • FIG. 3, trace a shows the vWF multimer pattern of vWF in the cryoprecipitate, trace b in the passage, trace c the 400 mM NaCl eluate (fraction 2, table 4), trace d the passage (fraction 1, table 4) cation exchange chromatography, lane passage through cation exchanger, lane f the 200 mM NaCl eluate (fraction 1, Table 5), lane g the 300 mM NaCl-eluate (fraction 2, Table 5) and lane h the 400 mM NaCl-eluate (fraction 3, Table 5).
  • the vWF multimer structure of the vWF in the fractions obtained with 200 mM NaCl (lane f) or, 300 mM NaCl (lane g) and 400 mM NaCl (lane h) after cation exchange chromatography is shown correspondingly.
  • the 400 mM NaCl eluate (lane h) shows a high molecular weight vWF multimer pattern and contains more than 70% of the vWF activity (currently considered by the Applicant to be the best mode for carrying out the invention).
  • vWF was produced by recombinant CHO cells in a common culture medium. After fermentation of the transformed cells, the culture medium was taken out, cells and cell debris were removed by centrifugation. Subsequently, the solution for removing low-molecular components, such as membrane fragments, was filtered through filters having a pore size of 0.4 ⁇ m.
  • the 280 mM NaCl-eluate of the anion exchange step was applied to an immobilized antibody resin (column dimension: 19.6 cm 2 x 5.6 cm, gel bed volume: 110 ml, resin matrix: Sepharose CL2B, antibodies: Fab fragments of the murine monoclonal antibody AvW8 / 2) equilibrated with 20 mM Na-acetate, 300 mM NaCl, (pH 7.0) at a flow rate of 0.255 cm / min. Subsequently, rinsing was carried out with 20 mM Na-acetate, 300 mM NaCl (pH 7.0) to which 0.5% Tween 80 had been added. r-vWF was eluted with 20mM glycine buffer to which 10% sucrose was added at pH 8.0. After 80% of the column volume, the flow rate was reduced by about 20-fold.
  • immobilized antibody resin column dimension: 19.6 cm 2 x 5.6 cm, gel bed volume: 110 ml
  • a chromatography column (7.1 cm 2 x 8 cm, filled with 57 ml of Fractogel ® EMD S03) was diluted with buffer (30 mM glycine-NaC1 buffer; pH 5.0) rinsed. Subsequently, the eluate of the immunoaffinity chromatography was filtered through the cation exchange column. After rewashing the column with 30 mM glycine-NaCl buffer, concomitants bound to the cation exchanger and low specific activity vWF were removed by rinsing the column with buffered 0.3 M NaCl solution. Subsequently, vWF was obtained from the exchanger column by elution with buffer containing 0.5 M NaCl in fraction 3.
  • vWF Ag
  • vWF ristocetin cofactor activity
  • rvWF is enriched by the factor 2.3 by anion exchange chromatography.
  • a further enrichment by a factor of 3.6 By the subsequent cation exchange chromatography, the vWF could be enriched again by a factor of 5.2.
  • this step virtually completely removed the traces of murine antibody present in the immunoaffinity column eluate ( ⁇ 0.02 mg / 1000 U vWF RistCoF activity).
  • Subsequent cation exchange chromatography separated the low molecular weight vWF multimers and enriched vWF with high molecular weight multimeric structures, thereby increasing the ratio of vWF: RistCoF to vWF: Ag activity by a factor of 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Confectionery (AREA)
  • Detergent Compositions (AREA)

Claims (18)

  1. Procédé d'obtention de vWF, caractérisé en ce que, à une concentration de sel de ≤ 250 mM, le vWF est fixé sur un échangeur de cations et, à une concentration de sel de > 300 mM, est obtenu par élution fractionnée avec une haute activité spécifique, comprenant en particulier des multimères du vWF.
  2. Procédé selon la revendication 1, caractérisé en ce que les fractions contenant le vWF, qui contiennent des multimères de vWF de haut poids moléculaire, sont éluées dans un tampon avec un pH dans l'intervalle entre 5,0 et 8,5, de préférence entre 6,0 et 8,0.
  3. Procédé selon l'une quelconque des revendications 1 à 2, caractérisé en ce que des multimères de vWF de bas poids moléculaire, des produits de dégradation protéolytique du vWF avec une faible activité spécifique et des protéines accompagnatrices inspécifiques sont éliminés à une concentration en sel de > 250 mM et ≤ 300 mM.
  4. Procédé selon l'une quelconque des revendications 1 à 3, caractérisé en ce que l'échangeur de cations est un porteur conjugué de groupes sulfopropyles ou carboxyméthyles.
  5. Procédé selon l'une quelconque des revendications 1 à 4, caractérisé en ce qu'une ou des fractions contenant le vWF, contenant en particulier des multimères de vWF de haut poids moléculaire, sont obtenues avec une activité spécifique d'agglutination de plaquettes d'au moins 65 U/mg de protéine et une activité spécifique de fixation du collagène d'au moins 65 U/mg.
  6. Procédé selon l'une quelconque des revendications 1 à 5, caractérisé en ce que la ou les fractions de vWF obtenues sont exemptes de multimères de vWF de bas poids moléculaire, de fragments de vWF avec une faible activité de vWF, et d'acides nucléiques contaminateurs.
  7. Procédé selon l'une quelconque des revendications 1 à 6, caractérisé en ce que du vWF avec une haute activité spécifique est obtenu à partir de plasma, d'une fraction de plasma, d'un cryoprécipité, du liquide surnageant ou d'un extrait d'une culture cellulaire recombinante, ou d'une solution de protéines enrichie.
  8. Procédé selon la revendication 7, caractérisé en ce que la solution de protéines enrichie est obtenue par une étape de purification la précédant.
  9. Procédé selon la revendication 8, caractérisé en ce que la solution de protéines enrichie est obtenue par un procédé chromatographique, tel une chromatographie sur échangeurs d'anions ou une chromatographie par affinités, ou par une combinaison des deux.
  10. Procédé selon l'une quelconque des revendications 1 à 9, caractérisé en ce que la ou les fractions obtenues, contenant du vWF, sont traitées pour une inactivation, respectivement un appauvrissement des/en virus.
  11. Préparation contenant du vWF purifié, consistant en particulier en multimères de vWF de haut poids moléculaire, pouvant être obtenue à partir d'une solution de protéines contenant du vWF par un procédé selon l'une quelconque des revendications 1 à 10.
  12. Préparation selon la revendication 11, caractérisée en ce qu'elle ne contient essentiellement pas de multimères de vWF de bas poids moléculaire, de produits inactifs de décomposition du vWF, ni d'acides nucléiques contaminateurs.
  13. Préparation selon la revendication 11 ou 12, caractérisée en ce qu'elle contient du vWF avec une activité spécifique d'agglutination de plaquettes d'au moins 65 U/mg de protéine et une activité spécifique de fixation du collagène d'au moins 65 U/mg.
  14. Préparation selon l'une quelconque des revendications 11 à 13, caractérisée en ce qu'elle est essentiellement exempte de facteur VIII et qu'elle comporte une teneur en facteur VIII de < 0,1 % en référence au rapport de l'activité du vWF au facteur VIII: C.
  15. Préparation selon l'une quelconque des revendications 11 à 14, caractérisée en ce qu'elle est virologiquement sûre.
  16. Préparation selon l'une quelconque des revendications 11 à 15, caractérisée en ce qu'elle se présente sous une forme stable au stockage.
  17. Préparation selon l'une quelconque des revendications 11 à 16, caractérisée en ce qu'elle est formulée comme préparation pharmaceutique.
  18. Utilisation d'une préparation selon l'une quelconque des revendications 11 à 17 à la production d'un médicament pour le traitement de patients atteint d'hémophilie phénotypique.
EP98901870A 1997-02-27 1998-02-18 Purification du facteur de von willebrand par chromatographie sur echangeur de cations Expired - Lifetime EP1005492B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0033797A AT405403B (de) 1997-02-27 1997-02-27 Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT33797 1997-02-27
PCT/AT1998/000034 WO1998038219A1 (fr) 1997-02-27 1998-02-18 Purification du facteur de von willebrand par chromatographie sur echangeur de cations

Publications (2)

Publication Number Publication Date
EP1005492A1 EP1005492A1 (fr) 2000-06-07
EP1005492B1 true EP1005492B1 (fr) 2007-04-11

Family

ID=3487918

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98901870A Expired - Lifetime EP1005492B1 (fr) 1997-02-27 1998-02-18 Purification du facteur de von willebrand par chromatographie sur echangeur de cations

Country Status (11)

Country Link
US (1) US6465624B1 (fr)
EP (1) EP1005492B1 (fr)
JP (1) JP4250770B2 (fr)
AT (2) AT405403B (fr)
AU (1) AU737986B2 (fr)
CA (1) CA2282843C (fr)
DE (1) DE59813967D1 (fr)
DK (1) DK1005492T3 (fr)
ES (1) ES2285754T3 (fr)
NO (1) NO324659B1 (fr)
WO (1) WO1998038219A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
AT408443B (de) * 1998-02-27 2001-11-26 Immuno Ag Verfahren zur gewinnung von gereinigtem faktor viii:c/vwf-komplex
US6605222B1 (en) * 1998-05-20 2003-08-12 Baxter Aktiengesellschaft Method for producing a factor VIII/von Willebrand factor complex
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
BRPI0514984A (pt) 2004-09-07 2008-07-01 Archemix Corp aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512097A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
DE102004044419B4 (de) 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
DE102004044429B4 (de) 2004-09-14 2009-04-30 Biotest Ag Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
EP1835938B1 (fr) 2004-12-27 2013-08-07 Baxter International Inc. Conjugues entre polymeres et facteurs von willebrand
US7683158B2 (en) 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
WO2008150495A2 (fr) * 2007-06-01 2008-12-11 Archemix Corp. Formulations d'aptamère vwf et procédés d'utilisation
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP3936116A1 (fr) * 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Formulations comprenant de vwf recombinant
PT2349314E (pt) * 2008-10-21 2013-05-28 Baxter Int Formulações de vwf recombinante liofilizado
AU2010284116B9 (en) * 2009-08-20 2015-03-26 Takeda Pharmaceutical Company Limited Purification of VWF for increased removal of non-lipid enveloped viruses
CA2821711C (fr) 2010-12-15 2017-10-10 Baxter International Inc. Recuperation d'eluat par utilisation d'un gradient de conductivite
EP3858375B1 (fr) * 2011-06-10 2024-03-20 Takeda Pharmaceutical Company Limited Traitement d'une maladie de la coagulation par l'administration du fvw recombinant
WO2015188224A1 (fr) 2014-06-13 2015-12-17 Csl Limited Production améliorée du facteur de von willebrand recombinant dans un bioréacteur
PT3648788T (pt) 2017-07-07 2024-08-23 Takeda Pharmaceuticals Co Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante
AU2019240135B2 (en) 2018-03-21 2024-10-03 Takeda Pharmaceutical Company Limited Separation of VWF and VWF propeptide by chromatographic methods
CA3161383A1 (fr) 2019-12-10 2021-06-17 Vera OTT Procede de fabrication d'une preparation de fibrinogene

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US5006642A (en) 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
DE3904354A1 (de) 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IT1256622B (it) * 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
CA2159044A1 (fr) 1994-09-26 1996-03-27 Falko-Guenter Falkner Methode de dosage des acides nucleiques
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
US5887152A (en) 1995-04-12 1999-03-23 Advanced Micro Devices, Inc. Load/store unit with multiple oldest outstanding instruction pointers for completing store and load/store miss instructions

Also Published As

Publication number Publication date
JP2001513088A (ja) 2001-08-28
JP4250770B2 (ja) 2009-04-08
NO994138D0 (no) 1999-08-26
WO1998038219A1 (fr) 1998-09-03
NO994138L (no) 1999-08-26
EP1005492A1 (fr) 2000-06-07
AU737986B2 (en) 2001-09-06
CA2282843C (fr) 2008-12-02
ES2285754T3 (es) 2007-11-16
DK1005492T3 (da) 2007-08-13
AT405403B (de) 1999-08-25
CA2282843A1 (fr) 1998-09-03
ATE359301T1 (de) 2007-05-15
NO324659B1 (no) 2007-11-26
US6465624B1 (en) 2002-10-15
ATA33797A (de) 1998-12-15
AU5847098A (en) 1998-09-18
DE59813967D1 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
EP1005492B1 (fr) Purification du facteur de von willebrand par chromatographie sur echangeur de cations
EP0784632B1 (fr) Procede pour l&#39;extraction du facteur willebrand a haute purete
DE68922358T3 (de) Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen.
EP0888386B1 (fr) Complexe stable facteur de von willebrand/facteur viii
AT406866B (de) Hochmolekulare und niedermolekulare fraktionen des von willebrand-faktors
EP0971958B2 (fr) PROCEDE DE PURIFICATION D&#39;UN COMPLEXE FACTEUR VIII/FACTEUR DE VON WILLEBRAND (vWF) PAR CHROMATOGRAPHIE SUR ECHANGEUR DE CATIONS
DE69017050T2 (de) Verfahren zur isolierung von faktor viii.
EP1012191B1 (fr) PROCEDE PERMETTANT D&#39;OBTENIR UN FACTEUR DE VON WILLEBRAND (vWF) OU UN COMPLEXE FACTEUR VIII
EP1817338B1 (fr) Production d&#39;une preparation de facteur willebrand presentant une haute activite specifique
DE69221369T2 (de) Verfahren zur Herstellung eines Konzentrates von Blutgerinnungsfaktor XI mit hoher spezifischer Aktivität zur therapeutischen Verwendung
DE69829408T2 (de) Herstellungsverfahren einer virusfreien faktor viii-lösung durch filtration
AT403765B (de) Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
EP1789444B1 (fr) Production d&#39;une preparation de facteur willebrand au moyen d&#39;hydroxylapatite
AT404358B (de) Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
DE19616540A1 (de) Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
DE19616540A9 (de) Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990914

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 19990914

17Q First examination report despatched

Effective date: 20050504

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL SE

AX Request for extension of the european patent

Extension state: SI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070411

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

RIN2 Information on inventor provided after grant (corrected)

Inventor name: EIBL, JOHANN

Inventor name: DORNER, FRIEDRICH

Inventor name: FIEDLER, CHRISTIAN

Inventor name: MITTERER, ARTUR

Inventor name: SCHOENBERGER, OEYVIND, L.

Inventor name: FISCHER, BERNHARD

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE S.A.

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REF Corresponds to:

Ref document number: 59813967

Country of ref document: DE

Date of ref document: 20070524

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070711

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20070622

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2285754

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20080114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070712

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 59813967

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 59813967

Country of ref document: DE

Owner name: BAXALTA GMBH, GLATTPARK, CH

Free format text: FORMER OWNER: BAXTER AG, WIEN, AT

Ref country code: DE

Ref legal event code: R081

Ref document number: 59813967

Country of ref document: DE

Owner name: BAXALTA INCORPORATED, BANNOCKBURN, US

Free format text: FORMER OWNER: BAXTER AG, WIEN, AT

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: BAXTER EASTERN EUROPE VERTRIEBS GMBH; AT

Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), VERANDERING VAN DE JURIDISCHE ENTITEIT; FORMER OWNER NAME: BAXTER AKTIENGESELLSCHAFT

Effective date: 20160502

Ref country code: NL

Ref legal event code: HC

Owner name: BAXALTA INNOVATIONS GMBH; AT

Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), VERANDERING VAN NAAM VAN DE EIGENAAR(S); FORMER OWNER NAME: BAXTER TRADING GMBH

Effective date: 20160502

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: BAXALTA INCORPORATED; US

Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT; FORMER OWNER NAME: BAXTER AKTIENGESELLSCHAFT

Effective date: 20160524

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20160519 AND 20160525

REG Reference to a national code

Ref country code: FR

Ref legal event code: TQ

Owner name: BAXALTA INNOVATIONS GMBH

Effective date: 20160518

Ref country code: FR

Ref legal event code: TQ

Owner name: BAXALTA INCORPORATED, US

Effective date: 20160518

Ref country code: FR

Ref legal event code: CJ

Effective date: 20160518

Ref country code: FR

Ref legal event code: CD

Owner name: BAXALTA INNOVATIONS GMBH

Effective date: 20160518

Ref country code: FR

Ref legal event code: CD

Owner name: BAXALTA INCORPORATED, US

Effective date: 20160518

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 359301

Country of ref document: AT

Kind code of ref document: T

Owner name: BAXALTA GMBH, CH

Effective date: 20160623

Ref country code: AT

Ref legal event code: PC

Ref document number: 359301

Country of ref document: AT

Kind code of ref document: T

Owner name: BAXALTA INCORPORATED, US

Effective date: 20160623

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: BAXALTA GMBH

Effective date: 20160823

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: BAXTER INNOVATIONS GMBH, AT

Free format text: FORMER OWNER: BAXTER TRADING GMBH, AT

Ref country code: CH

Ref legal event code: PFA

Owner name: BAXTER EASTERN EUROPE VERTRIEBS GMBH, AT

Free format text: FORMER OWNER: BAXTER AKTIENGESELLSCHAFT, AT

Ref country code: CH

Ref legal event code: PFA

Owner name: BAXTER TRADING GMBH, AT

Free format text: FORMER OWNER: BAXTER EASTERN EUROPE VERTRIEBS GMBH, AT

Ref country code: CH

Ref legal event code: PFA

Owner name: BAXALTA INNOVATIONS GMBH, AT

Free format text: FORMER OWNER: BAXTER INNOVATIONS GMBH, AT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: BAXALTA INCORPORATED, CH

Free format text: FORMER OWNER: BAXALTA INNOVATIONS GMBH, AT

Ref country code: CH

Ref legal event code: NV

Representative=s name: KELLER AND PARTNER PATENTANWAELTE AG, CH

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170223

Year of fee payment: 20

Ref country code: CH

Payment date: 20170227

Year of fee payment: 20

Ref country code: DE

Payment date: 20170227

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20170227

Year of fee payment: 20

Ref country code: AT

Payment date: 20170201

Year of fee payment: 20

Ref country code: LU

Payment date: 20170227

Year of fee payment: 20

Ref country code: NL

Payment date: 20170226

Year of fee payment: 20

Ref country code: IE

Payment date: 20170228

Year of fee payment: 20

Ref country code: DK

Payment date: 20170223

Year of fee payment: 20

Ref country code: BE

Payment date: 20170227

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20170223

Year of fee payment: 20

Ref country code: ES

Payment date: 20170227

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 59813967

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20180218

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20180217

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20180217

Ref country code: BE

Ref legal event code: PD

Owner name: BAXALTA GMBH; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AFFECTATION / CESSION; FORMER OWNER NAME: BAXTER INNOVATIONS GMBH

Effective date: 20160527

Ref country code: BE

Ref legal event code: MK

Effective date: 20180218

Ref country code: BE

Ref legal event code: HC

Owner name: BAXTER INNOVATIONS GMBH; AT

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT NOM PROPRIETAIRE; FORMER OWNER NAME: BAXTER AKTIENGESELLSCHAFT

Effective date: 20150601

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 359301

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180218

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180217

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180219